TheProductLawyers.com reports on claims made by plaintiffs in a new lawsuit filed against the makers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subsidiary company of the Johnson and Johnson Corporation The plaintiffs allege that the U.S. Food and Drug Administration (FDA) had sent the manufacturers written correspondence stating that claims made in their marketing campaign for Xarelto were misleading. However, despite the FDA letter, plaintiffs allege that Bayer and Janssen continued to advertise the blood thinner with no amendments made to their public outreach.
Loved Ones Of The Deceased File Suit
This newest wrongful death lawsuit centers on allegations of false claims made by the manufacturers of the drug and was filed on November 20, 2015, in St. Clair County Circuit Court by a group of 10 people whose family members had allegedly died from excessive bleeding through the use of Xarelto. All of the plaintiffs live in different states but they are cohesive in their claims that Xarelto caused the death of their loved ones.
In addition to this particular case, Xarelto lawsuits number in excess of 3,000 cases with over 2,800 as part of a multidistrict consolidation (MDL 2592) in a Louisiana federal court. 550 more cases have been grouped in a mass tort program in Philadelphia, Pennsylvania.
The court documents state that although Bayer and Janssen were aware of the possible dangerous side effects of the drug, they nonetheless marketed Xarelto as a safe and effective treatment for those suffering from a heart condition called atrial fibrillation and for those who had undergone knee and hip replacement surgeries. Plaintiffs claim Bayer and Janssen falsely promoted the drug using celebrity spokespersons and failed to adequately express to the public potentially dangerous side effects of the drug.
Nine counts of misconduct have been filed by the plaintiffs ranging from wrongful death to fraud and they are additionally seeking compensatory damages of $50,000 per deceased family member.